Related Experiment Video

Updated: Aug 20, 2025

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.7K

Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study

Epiphane Kolla1,2, Alain Weill1, David Desplas1

  • 1EPI-PHARE (Scientific Interest Group in Epidemiology of Health Products), French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, CEDEX, 93285 Saint-Denis, France.

Vaccines
|November 24, 2022
PubMed

Insights

This study found that the measles, mumps, and rubella (MMR) vaccine did not reduce the risk of COVID-19 hospitalization in children. The live attenuated MMR vaccine showed no protective effect against severe COVID-19 outcomes in pediatric populations.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Epidemiology

Background:

  • The lower incidence of severe COVID-19 in children compared to adults has led to hypotheses about potential cross-protection from existing live attenuated vaccines.
  • The measles, mumps, and rubella (MMR) vaccine, a widely administered live attenuated vaccine, has been investigated for potential non-specific immune effects.

Purpose of the Study:

  • To evaluate whether prior exposure to the live attenuated MMR vaccine influences the risk of hospitalization due to COVID-19 in children.
  • To investigate the association between MMR vaccination status and COVID-19 hospitalization rates in a large pediatric cohort.

Main Methods:

  • A nationwide cohort study was conducted using the French National Health Data System (SNDS), including children born between 2009 and 2019.
  • Exposure was defined as receiving at least one dose of the MMR vaccine. Hospitalization for COVID-19 was identified using ICD-10 codes.
  • Multivariate logistic regression analysis was employed to calculate adjusted odds ratios (aORs), controlling for relevant covariates.

Main Results:

  • The study included over 6.8 million children exposed to the MMR vaccine and over 384,000 unexposed children.
  • MMR vaccine exposure was not associated with a reduced risk of COVID-19 hospitalization (aOR = 1.09; 95% CI [0.81–1.48]).
  • Stratified analyses by age group (1-4, 5-9, 10-12 years) also revealed no significant protective effect of MMR vaccination against COVID-19 hospitalization.

Conclusions:

  • The findings suggest that the live attenuated MMR vaccine does not provide protection against hospitalization for COVID-19 in children.
  • The hypothesis of cross-protection from MMR vaccination against severe COVID-19 in pediatric populations is not supported by this study's results.

Keywords:
COVID-19MMR vaccineSNDShospitalizationsvaccination

More Related Videos

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.8K
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

2.0K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
45.2K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
169
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
12.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13